Jeffrey Holford

Jefferies said in a note Monday that upside asymmetry for Bristol-Myers Squibb Co (NYSE: BMY) is exhausted at current levels, with shares having already discounted M&A spec and biopharma flows. This, according to the firm, leaves significant downside risk if current study CM-227 fails. CM-...

The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference. Here’s a breakdown of the highlights. Five Prime Therapeutics Five Prime Therapeutics Inc (NASDAQ: FPRX) reported positive...

Consensus seems to be underappreciating “several key pipeline opportunities” for AbbVie Inc (NYSE: ABBV), including Rova-T in small cell lung cancer, Jefferies’ Jeffrey Holford said in a report. While maintaining a Buy rating and a price target of $90 on the company, the analyst...

Bristol-Myers Squibb Co (NYSE: BMY) shares spiked 4.5 percent Tuesday on news that Carl Icahn bought a stake in the company. According to the Wall Street Journal, Icahn allegedly considers Bristol-Myers a potential takeover target. Earlier Tuesday, Bristol-Myers reported a $2 billion accelerated...

Expressing concern related to the weakening pharma sector fundamentals and adverse macro environment, Jefferies' Jeffrey Holford mentioned in a report that the sector already reflects these concerns to some extent following the recent derating. Some of the most anticipated studies had failed in...

Pharma sector fundamentals have been weakening against an adverse macro environment, Jefferies' Jeffrey Holford said in a report. He added that although 2017 offered some important R&D catalysts, pharma stocks may remain under pressure. With some of the most anticipated studies failing in...

Jefferies remains bullish on AbbVie Inc (NYSE: ABBV) as management meetings suggest the next 12 months should see significant visibility emerge for its rheumatoid arthritis drug Humira biosimilars with the earliest potential U.S. launches only being seen post-2020. The brokerage reiterated its Buy...

Jefferies’ Jeffrey Holford believes there is a much higher probability of AstraZeneca plc (ADR) (NYSE: AZN) achieving success with the MYSTIC study, as well as larger market opportunity, than the consensus forecasts imply. Holford upgraded the rating on the company from Hold to Buy, while...

Jefferies analysts led by Jeffrey Holford and Ian Hilliker shared their monthly update on the global pharmaceuticals industry. The firm sees attractive catalysts in the sector, and believe fundamentals and valuation are alluring. However, “investors may need a little more patience whilst we...

There are a number of catalysts on the horizon for global pharma stocks, but Jefferies has dialed back expectations for a number of stocks in the space. In a new report, analyst Jeffrey Holford has updated the firm’s outlook and price targets for the biggest names in the pharma space. Despite...

Jefferies and analyst Jeffrey Holford recently released its monthly report on the global pharmaceuticals industry. The report includes Jefferies' top stock picks in the space, as well as a summary of key topics that investors should be watching. Standout Data  According to the report...